miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 16, 2026

Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc.

View original at globenewswire.com
Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc. MIAMI, June 17, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs, peneraju dalam dana dagangan bursa bertema dan berleveraj, hari ini mengumumkan bahawa Cboe BZX Exchange, Inc…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • For periods longer than one day, the fund's performance will be the result of compounded daily returns, which will almost certainly differ from 200% of the Target Portfolio's return over the same period

    60% confidence

  • The derivatives market (swaps, options) for SpaceX as a newly listed company may be limited, illiquid, highly volatile, expensive, or unavailable, which could increase tracking error or prevent the fund from achieving its investment objective

    60% confidence

  • SpaceX is expected to be a controlled company with voting power concentrated in founder Elon Musk through Class B common shares carrying 10 votes per share

    60% confidence

  • SPCL seeks daily investment results equal to 200% of the daily performance of its Target Portfolio

    60% confidence

  • An investor could lose the entire value of their principal investment in a single trading day

    60% confidence

  • SpaceX risks include new or unproven technology programs such as Starship, next-generation Starlink satellites, and orbital AI initiatives

    60% confidence

  • The SpaceX IPO constitutes a Material Space Event as defined in the amended Prospectus, which will cause the fund to hold all or a significant portion of its portfolio in instruments providing exposure to SpaceX shares

    60% confidence

  • Throughout the suspension period, the underlying portfolio assets remained secure and were unaffected by the trading suspension imposed by the Exchange

    60% confidence

  • SPCL's investment in SpaceX exposure relies on derivatives (swap agreements and listed option contracts) rather than directly holding underlying securities

    60% confidence

  • Defiance pioneered single-stock leveraged ETFs, allowing investors to take amplified positions in high-potential companies with precise leveraged exposure without opening a margin account

    60% confidence

  • The fund is intended for knowledgeable investors who understand the implications of seeking leveraged daily (2X) investment results and are prepared to monitor their portfolios frequently; it is not suitable for investors who do not intend to actively monitor and manage their portfolios

    60% confidence

  • The fund's investment results following a rebalancing in response to a Material Space Event may differ materially from prior results, and the fund may temporarily deviate from its targeted daily exposure level

    60% confidence

  • Cboe BZX Exchange has approved the resumption of trading in SPCL shares following the temporary suspension initiated by the Exchange on June 12, 2026

    60% confidence

Data points we hold from this source

Elon Musk · parameter count10 votes_per_Class_B_share
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
Defiance ETFs Mengumumkan Penyambungan Semula Dagangan bagi Defiance Daily 2X Space ETF (SPCL) di Cboe BZX Exchange, Inc. — Source | Via News | es.VIA.NEWS